

Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers — Issue 1

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements is true regarding patients with right-sided versus left-sided advanced colorectal cancer (CRC)?**
 - Patients with right-sided CRC have a better prognosis
 - Patients with right-sided, RAS wild-type CRC respond better to EGFR-targeted therapy
 - Patients with left-sided, RAS wild-type CRC respond better to EGFR-targeted therapy
- 2. Which of the following conditions is an adverse event of special interest with trastuzumab deruxtecan in patients with HER2-expressing gastric adenocarcinoma?**
 - New secondary cancer
 - Ocular toxicity
 - Interstitial lung disease
- 3. The CheckMate 648 study evaluated nivolumab with ipilimumab or nivolumab with chemotherapy versus chemotherapy alone for patients with advanced esophageal squamous cell carcinoma in which setting?**
 - First line
 - Second line
 - Third line
- 4. Which of the following drug types best describes tivozanib?**
 - Immune checkpoint inhibitor
 - Antibody-drug conjugate
 - VEGFR tyrosine kinase inhibitor
- 5. What was the progression-free survival outcome in the KEYNOTE-177 trial investigating pembrolizumab versus investigator's choice of chemotherapy for patients with MSI (microsatellite instability)-high advanced CRC?**
 - Significant improvement with pembrolizumab
 - No significant difference between the study arms